BML-210

CAS No. 537034-17-6

BML-210( BML210 | BML 210 )

Catalog No. M14907 CAS No. 537034-17-6

A novel histone deacetylase (HDAC) inhibitor that induces Ac-histone in A549 cells with EC50 of 181 uM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 31 In Stock
5MG 48 In Stock
10MG 69 In Stock
25MG 115 In Stock
50MG 186 In Stock
100MG 332 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BML-210
  • Note
    Research use only, not for human use.
  • Brief Description
    A novel histone deacetylase (HDAC) inhibitor that induces Ac-histone in A549 cells with EC50 of 181 uM.
  • Description
    A novel histone deacetylase (HDAC) inhibitor that induces Ac-histone in A549 cells with EC50 of 181 uM; inhibits the growth of all cell lines and promotes apoptosis in the human leukemia cell lines (NB4, HL-60, THP-1, and K562); induces growth inhibition and apoptosis and downregulates HDAC1-5 and DAPC complex expression levels in cervical cancer cells.
  • In Vitro
    Cell Proliferation AssayCell Line:NB4 cells Concentration:10, 20 μM Incubation Time:24, 48 hours Result:Inhibited cell proliferation and growth inhibition of NB4 cells in a dose- and time-dependent manner.Cell Cycle AnalysisCell Line:NB4 cells Concentration:10, 20 μM Incubation Time:24, 48 hours Result:Caused a decrease in the proportion of NB4 cells in the S phase and an increase in the G0/G1 phase.Caused an increase in the G0/G1 phase up to 70% at 24 and 48 h with 10 μM.Cell Cytotoxicity Assay Cell Line:NB4 cells Concentration:10, 20 μM Incubation Time:24, 48 hours Result:Caused cytotoxic effects on NB4 cells in a dose- and time-dependent manner.Apoptosis Analysis Cell Line:NB4 cells Concentration:10, 20 μM Incubation Time:24, 48 hours Result:At a dose of 10 μM induced apoptotic cell death.Western Blot Analysis Cell Line:NB4 cells Concentration:10, 20 μM Incubation Time:24, 48 hours Result:At 10 μM dose inhibited HDAC1 gene expression up to 36% after 48 h of treatment Inhibited HDAC expression up to 74% at 8 h point at 20 μM.
  • In Vivo
    Animal Model:Female C57BL/6 mice with mouse breast cancer EO771 cells Dosage:20 mg/kg Administration:IP; three times per week for two weeks Result:Notably suppressed the tumour growth and weight.
  • Synonyms
    BML210 | BML 210
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    HDAC
  • Recptor
    HDAC
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    537034-17-6
  • Formula Weight
    339.4314
  • Molecular Formula
    C20H25N3O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 30 mg/mL
  • SMILES
    O=C(NC1=CC=CC=C1N)CCCCCCC(NC2=CC=CC=C2)=O
  • Chemical Name
    Octanediamide, N1-(2-aminophenyl)-N8-phenyl-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Savickiene J, et al. Eur J Pharmacol. 2006 Nov 7;549(1-3):9-18. 2. Wong JC, et al. J Am Chem Soc. 2003 May 14;125(19):5586-7. 3. Borutinskaite VV, et al. Mol Biol Rep. 2012 Dec;39(12):10179-86.
molnova catalog
related products
  • EDO-S101

    EDO-S101 (Tinostamustine)?is a fusion molecule comprising of the alkylator bendamustine and the HDAC-inhibitor vorinostat.

  • ACY-241

    ACY-241, also known as Citarinostat, is a potent, selective and orally available histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity.

  • Trichostatin A (TSA)

    Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM – HDAC8 is the only known member of the HDAC-family that is not affected by TSA.